NasdaqCM:TGTXBiotechs
How BRIUMVI’s Strong High‑Risk MS Data At TG Therapeutics (TGTX) Has Changed Its Investment Story
TG Therapeutics recently reported that a post hoc pooled analysis of the Phase 3 ULTIMATE I and II trials, published in Neurology and Therapy, showed BRIUMVI delivered statistically significant improvements over teriflunomide in relapse rates, MRI activity, and NEDA-3 outcomes for people with highly active relapsing multiple sclerosis over 96 weeks.
This peer‑reviewed analysis of a high‑risk subgroup, with benefits emerging by Week 12 and maintained through nearly two years, may strengthen...